Sign up

Redmile Group, LLC

$1.5B assets · 39 holdings · Q2 2026 · Filed 14 AUG 2026

About Redmile Group, LLC’s 13F portfolio

Redmile Group, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Redmile Group, LLC reported $1.5B across 39 US-listed positions (). Its largest position is SCHOLAR ROCK HLDG CORP (SRRK) at 16% of the reported book, and its ten biggest holdings make up 73% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$1.5B
Assets (13F)
#1,843
of 8,839 by size
39
Holdings
73%
Top-10 weight
9
Buys
23
Sells
Top holdings · Q2 2026
39 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: SRRK
SCHOLAR ROCK HLDG CORP
$48.00
+6.48%
16%
4.3M$237.1M
2
NASDAQ: KRYS
KRYSTAL BIOTECH INC
$315.34
+5.62%
16%
632K$234.9M
3
NASDAQ: STOK
STOKE THERAPEUTICS INC
$26.69
+1.06%
8.7%
3.9M$129.1M
4
NASDAQ: IMNM
IMMUNOME INC
$16.78
−2.33%
7.0%
4.9M$104.1M
5
NASDAQ: NRIX
NURIX THERAPEUTICS INC
$14.10
−0.98%
6.6%
4.1M$98.8M
6
NASDAQ: ABSI
ABSCI CORPORATION
$8.18
+7.92%
5.2%
6.7M$78.1M
7
NASDAQ: ANNX
ANNEXON INC
$3.52
+1.44%
4.6%
11.9M$67.8M
8
NASDAQ: RGNX
REGENXBIO INC
$7.26
+0.28%
3.5%
4.4M$52.3M
9
NASDAQ: STTK
SHATTUCK LABS INC
$4.47
−2.61%
3.2%
6.9M$47.8M
10
NASDAQ: NGNE
NEUROGENE INC
$23.14
+0.17%
3.0%
1.4M$44.4M
11
NASDAQ: BEAM
BEAM THERAPEUTICS INC
$21.01
+1.74%
2.7%
1.2M$40.0M
12
NASDAQ: AGMB
AGOMAB THERAPEUTICS NV
—
—
2.4%
2.7M$35.5M
13
NASDAQ: FATE
FATE THERAPEUTICS INC
$1.05
+2.94%
2.3%
12.9M$34.8M
14
NASDAQ: IDYA
IDEAYA BIOSCIENCES INC
$26.49
−3.32%
1.6%
640K$23.9M
15
NASDAQ: SLN
SILENCE THERAPEUTICS PLC
$19.82
+0.10%
1.6%
2.2M$23.8M
16
NASDAQ: COGT
COGENT BIOSCIENCES INC
$27.81
−0.14%
1.3%
503K$19.5M
17
NASDAQ: SLDB
SOLID BIOSCIENCES INC
$6.35
+1.93%
1.3%
1.9M$19.5M
18
NYSE: NUVB
NUVATION BIO INC
$3.78
−3.08%
1.2%
3.0M$17.2M
19
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC NEW
$27.55
−1.75%
1.1%
434K$16.1M
20
NASDAQ: CLYM
CLIMB BIO INC
$9.30
−4.91%
1.1%
1.2M$16.0M
21
NASDAQ: ALXO
ALX ONCOLOGY HLDGS INC
$0.97
−3.47%
1.0%
7.4M$15.3M
22
NASDAQ: BMRN
BIOMARIN PHARMACEUTICAL INC
$61.43
+4.99%
1.0%
265K$15.2M
23
NASDAQ: XENE
XENON PHARMACEUTICALS INC
$37.75
−2.66%
0.9%
229K$13.8M
24
NASDAQ: ZYME
ZYMEWORKS INC
$26.04
+0.77%
0.9%
492K$12.9M
25
NYSE: ADCT
ADC THERAPEUTICS SA
$1.37
+1.48%
0.8%
11.5M$12.3M

Showing 1–25 of 39 positions on this page reported in this 13F.

Sector allocation
  • Healthcare97%
Recent activity · vs 2026-03-31
Bought9
  • AddedSTTKSHATTUCK LABS INC+24.4%$47.8M
  • AddedAGMBAGOMAB THERAPEUTICS NV+1650%$35.5M
  • AddedIDYAIDEAYA BIOSCIENCES INC+22.9%$23.9M
  • AddedCLDXCELLDEX THERAPEUTICS INC NEW+65.9%$16.1M
  • NewCLYMCLIMB BIO INC—$16.0M
  • AddedBMRNBIOMARIN PHARMACEUTICAL INC+52.5%$15.2M
  • NewAURAAURA BIOSCIENCES INC—$11.8M
  • NewODTXODYSSEY THERAPEUTICS INC—$8.0M
  • NewINSMINSMED INC—$5.5M
Sold23
  • ReducedSRRKSCHOLAR ROCK HLDG CORP−52.5%$237.1M
  • ReducedKRYSKRYSTAL BIOTECH INC−6.2%$234.9M
  • ReducedSTOKSTOKE THERAPEUTICS INC−5.2%$129.1M
  • ReducedIMNMIMMUNOME INC−11.6%$104.1M
  • ReducedNRIXNURIX THERAPEUTICS INC−47.3%$98.8M
  • ReducedABSIABSCI CORPORATION−18.3%$78.1M
  • ReducedANNXANNEXON INC−18.4%$67.8M
  • ReducedNGNENEUROGENE INC−3.2%$44.4M
  • ReducedBEAMBEAM THERAPEUTICS INC−5.9%$40.0M
  • ReducedCOGTCOGENT BIOSCIENCES INC−26.8%$19.5M
5%+ Beneficial Ownership Stakes · 4 activist (13D) · 11 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
FATE
FATE THERAPEUTICS INC
13D15.0% · 2 classes19.2MFiled 09 NOV 2026
2
ANNX
Annexon, Inc.
13G9.9% · 2 classes17.9MFiled 08 JUL 2026
3
ADCT
ADC Therapeutics SA
13G9.9% · 2 classes12.7MFiled 24 APR 2026
4
SRRK
Scholar Rock Holding Corporation
13G9.9%9.9MFiled 14 FEB 2025
5
STTK
Shattuck Labs, Inc.
13D9.9% · 2 classes6.4MFiled 26 AUG 2025
6
RGNX
REGENXBIO Inc.
13G9.9%5.1MFiled 14 AUG 2025
7
—
RAPT Therapeutics, Inc.
13G9.9%1.8MFiled 14 AUG 2025
8
ATRA
Atara Biotherapeutics, Inc.
13D9.9% · 2 classes951KFiled 24 JUL 2026
9
ETRA
Electra Therapeutics, Inc.
13G8.7%5.5MFiled 28 SEP 2026
10
ALXO
ALX Oncology Holdings Inc.
13G8.5% · 2 classes4.6MFiled 14 AUG 2025
11
—
Gritstone bio, Inc.
13G8.2%13.2MFiled 14 FEB 2025
12
NRIX
Nurix Therapeutics, Inc.
13G8.1%8.8MFiled 14 AUG 2026
13
STOK
Stoke Therapeutics, Inc.
13G8.0% · 2 classes4.4MFiled 14 AUG 2025
14
ABSI
Absci Corporation
13D6.5%8.3MFiled 29 APR 2025
15
IMNM
Immunome, Inc.
13G5.2%5.7MFiled 17 FEB 2026

Showing all 15 disclosed stakes. 8 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Redmile Group, LLC’s 13F portfolio

Redmile Group, LLC’s $1.5B 13F book is spread across 39 reported positions and is highly concentrated — its ten largest positions alone are 73% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are SRRK, KRYS, STOK, IMNM and NRIX, led by SCHOLAR ROCK HLDG CORP (SRRK) at 16% of the portfolio. The heaviest sector exposure is Healthcare (97%).

What Redmile Group, LLC changed last quarter

Between 2026-03-31 and Q2 2026, Redmile Group, LLC was a net seller: it opened 4 new positions and added to 5 more, while trimming 23 and closing 0 outright. Against a 39-name book, that is moderate turnover, pointing to steady rotation within the portfolio. Its largest new or increased position was SHATTUCK LABS INC (STTK), and its biggest reduction was SCHOLAR ROCK HLDG CORP (SRRK).

What a 13F does and doesn’t reveal

A 13F captures only Redmile Group, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Redmile Group, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Redmile Group, LLC's profile on this page is built directly from those filings.

How current is the 13F data on Redmile Group, LLC's page?

It reflects Redmile Group, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Redmile Group, LLC files its next quarterly report, this page refreshes automatically.

Can I see Redmile Group, LLC's complete list of holdings?

This page highlights Redmile Group, LLC's largest positions rather than all 39 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Redmile Group, LLC's filings.

Does a 13F show everything Redmile Group, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Redmile Group, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Redmile Group, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.